<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04384367</url>
  </required_header>
  <id_info>
    <org_study_id>EF167</org_study_id>
    <nct_id>NCT04384367</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of Migraine</brief_title>
  <official_title>A Multicenter, Double-blind, Double-dummy, Randomized, Single-dose, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rizatriptan-Naproxen (10/550 mg) in the Acute Treatment of Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eurofarma Laboratorios S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eurofarma Laboratorios S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase III study, multicenter, double-blind, double-dummy, randomized, single-dose,
      placebo-controlled study to evaluate the efficacy and safety of Rizatriptan-Naproxen (10/550
      mg) in the acute treatment of migraine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, double-blind, double-dummy and placebo-controlled study in
      individuals with disabling migraine. The participants will be randomized to receive
      Rizatriptan + Naproxen (10/550mg), Rizatriptan (10mg), Naproxen (550mg) or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 28, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-hour pain-free</measure>
    <time_frame>11 weeks</time_frame>
    <description>2-hour pain-free response (Proportion of participants reporting pain freedom at two hours post-dose)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Most bothersome migraine‚Äêassociated symptom</measure>
    <time_frame>11 weeks</time_frame>
    <description>Migraine-associated symptoms: nausea, vomiting, photophobia or phonophobia and phonophobia (frequency)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1524</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Rizatriptan 10mg+ Naproxen 550mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rizatriptan 10mg+ Naproxen 550mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maxalt 10mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rizatriptan10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flanax 550mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naproxen 550mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rizatriptan 10 mg + Naproxen 550mg</intervention_name>
    <description>oral - single dose</description>
    <arm_group_label>Rizatriptan 10mg+ Naproxen 550mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maxalt 10Mg Tablet</intervention_name>
    <description>oral - single dose</description>
    <arm_group_label>Maxalt 10mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flanax 550mg</intervention_name>
    <description>oral - single dose</description>
    <arm_group_label>Flanax 550mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>oral - single dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of both sexes;

          -  Aged between 18 and 65 years old;

          -  Capable and willing to give free and informed informed consent in writing;

          -  Migraine patients with or without aura, according to the International Headache
             Society (IHS).

        Exclusion Criteria:

          -  Chronic migraine;

          -  Headache other than migraine (that is, tension-type headache, sinusitis, etc.).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laura Caram</last_name>
    <phone>+55 11 50908217</phone>
    <email>laura.caram@eurofarma.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cassiano Berto</last_name>
    <phone>+55 11 50908412</phone>
    <email>cassiano.berto@eurofarma.com.br</email>
  </overall_contact_backup>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 6, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Rizatriptan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

